急性冠脉综合征患者外周血lncRNA TPRG1‑AS1的表达及预后价值

李威; 贺立群; 张帆

doi:10.14188/j.1671-8852.2024.0663

您当前的位置：

首页 >

文章列表页 >

急性冠脉综合征患者外周血lncRNA TPRG1‑AS1的表达及预后价值

临床医学研究 | 更新时间：2026-11-05

- 急性冠脉综合征患者外周血lncRNA TPRG1‑AS1的表达及预后价值
- Expression and prognostic value of lncRNA TPRG1‑AS1 in peripheral blood of patients with acute coronary syndrome
- 武汉大学学报（医学版） 2025年46卷第10期页码：1301-1306
- 作者机构：
  
  武汉市第一医院心内科湖北武汉 430022
- 作者简介：
  
  李威，男，1992—，医学硕士，住院医师，主要从事冠心病的发生发展及机制研究，E‑mail:8869363054@qq.com
  张帆，男，1978—，医学硕士，副主任医师，主要从事心血管疾病的研究，E‑mail:13720277068@126.com
- 基金信息：
  
  湖北省卫生健康委科研项目(WJ2023F043)
- DOI：10.14188/j.1671-8852.2024.0663
  中图分类号： R541.4
- 收稿：2024-09-01，
  
  纸质出版：2025-10-25
- 稿件说明：
移动端阅览
李威,贺立群,张帆.急性冠脉综合征患者外周血lncRNA TPRG1‑AS1的表达及预后价值[J].武汉大学学报（医学版）,2025,46(10):1301-1306.

LI Wei,HE Liqun,ZHANG Fan.Expression and prognostic value of lncRNA TPRG1‑AS1 in peripheral blood of patients with acute coronary syndrome[J].Medical Journal of Wuhan University,2025,46(10):1301-1306.
李威,贺立群,张帆.急性冠脉综合征患者外周血lncRNA TPRG1‑AS1的表达及预后价值[J].武汉大学学报（医学版）,2025,46(10):1301-1306. DOI： 10.14188/j.1671-8852.2024.0663.

LI Wei,HE Liqun,ZHANG Fan.Expression and prognostic value of lncRNA TPRG1‑AS1 in peripheral blood of patients with acute coronary syndrome[J].Medical Journal of Wuhan University,2025,46(10):1301-1306. DOI： 10.14188/j.1671-8852.2024.0663.

摘要

目的

探讨长链非编码RNA（lncRNA）TPRG1‑AS1在急性冠脉综合征（ACS）发病和发展过程中的表达和意义，旨在探索一种新型生物标志物，用于ACS的诊断和预后。

方法

共纳入109名ACS患者和66名接受冠状动脉造影术但排除ACS的患者，通过PCR分析研究对象血清中的TPRG1‑AS1，通过ROC分析评估TPRG1‑AS1在筛查ACS中的意义，采用Pearson相关性检验评价TPRG1‑AS1与ACS疾病严重程度的关系。采用Logistic回归分析评估TPRG1‑AS1预测主要心血管不良事件（MACE）发生的潜在关系。

结果

在ACS患者血清中TPRG1‑AS1的表达显著上调，是ACS的危险因素。TPRG1‑AS1与ACS患者的Gensini评分、胱抑素C(Cys⁃C)、心肌肌钙蛋白I(cTnI)和NT‑proBNP水平呈正相关。此外，血清TPRG1‑AS1的升高与患者住院期间MACE的高发生率有关，并被确定为ACS患者发生MACE的危险因素。

结论

血清中TPRG1‑AS1的升高可作为诊断ACS的生物标志物，对患者病情的严重程度有一定的预测价值。

Abstract

Objective

To explore the expression and significance of long non‑coding RNA (lncRNA) TPRG1‑AS1 in the pathogenesis and development of acute coronary syndrome (ACS)

in order to explore a novel biomarker for the diagnosis and prognosis of acute coronary syndrome.

Methods

A total of 109 patients with ACS and 66 patients receiving coronary angiography but excluding ACS were included in this study. The significance of TPRG1‑AS1 in screening ACS was evaluated by PCR analysis of serum TPRG1‑AS1 of the study subjects and ROC analysis. Pearson correlation test was used to evaluate the relationship between TPRG1⁃AS1 and disease severity of ACS. Logistic regression analysis was used to evaluate the potential relationship of TPRG1‑AS1 to predict the occurrence of major adverse cardiovascular events (MACE).

Results

The expression of TPRG1⁃AS1 in serum of patients with ACS was significantly up‑regulated

which is a risk factor for ACS. TPRG1‑AS1 is positively correlated with Gensini score

Cys⁃C

cTnI and NT‑proBNP levels of patients with ACS. In addition

elevated serum TPRG1‑AS1 is associated with a higher incidence of MACE during hospitalization and has been identified as a risk factor for MACE in patients with ACS.

Conclusion

The increase of serum TPRG1‑AS1 can be used as a biomarker for the diagnosis of ACS and has certain predictive value for the severity of the disease. Upregulated TPRG1‑AS1 in ACS served as a diagnostic biomarker and predicted the severe development of patients.

关键词

Keywords

references

AHMADI A , ARGULIAN E , LEIPSIC J , et al . From subclinical atherosclerosis to plaque progression and acute coronary events JACC state‑of‑the‑art review [J ] . J Am Coll Cardiol , 2019 , 74 ( 12 ): 1608 ‑ 1617 .

SMITH J N , NEGRELLI J M , MANEK M B , et al . Diagnosis and management of acute coronary syndrome: An evidence‑based update [J ] . J Am Board Fam Med , 2015 , 28 ( 2 ): 283 ‑ 293 .

BOYD B , ZAMORA C A , CASTILLO M . Managing adverse reactions to contrast agents [J ] . Magn Reson Imaging Clin N Am , 2017 , 25 ( 4 ): 737 ‑ 742 .

MARRACCINI P , BIANCHI M , FOMMEI E , et al . Contrast medium nephrotoxicity after renal artery and coronary angioplasty [J ] . Acta Radiol , 2010 , 51 ( 4 ): 462 ‑ 466 .

WANG L , JIN Y . Noncoding RNAs as biomarkers for acute coronary syndrome [J ] . Biomed Res Int , 2020 , 2020 : 3298696 .

LI L , WANG L Y , LI H F , et al . Characterization of LncRNA expression profile and identification of novel LncRNA biomarkers to diagnose coronary artery disease [J ] . Atherosclerosis , 2018 , 275 : 359 ‑ 367 .

REN X , ZHU H , DENG K , et al . Long noncoding RNA TPRG1‑AS1 suppresses migration of vascular smooth muscle cells and attenuates atherogenesis via interacting with MYH9 protein [J ] . Arterioscler Thromb Vasc Biol , 2022 , 42 ( 11 ): 1378 ‑ 1397 .

CHOI J H , KWON S M , MOON S U , et al . TPRG1‑AS1 induces RBM24 expression and inhibits liver cancer progression by sponging miR‑4691‑5p and miR‑3659 [J ] . Liver Int , 2021 , 41 ( 11 ): 2788 ‑ 2800 .

HE J N , DONG C M , ZHANG H , et al . The oncogenic role of TFAP2A in bladder urothelial carcinoma via a novel long noncoding RNA TPRG1‑AS1/DNMT3A/CRTAC1 axis [J ] . Cell Signal , 2023 , 102 : 110527 .

LI Z H , QIU X G , HE Q , et al . CCND1‑associated CeRNA network reveal the critical pathway of TPRG1‑AS1‑hsa‑miR‑363‑3p‑MYO1B as a prognostic marker for head and neck squamous cell carcinoma [J ] . Sci Rep , 2023 , 13 : 11831 .

KIMURA K , KIMURA T , ISHIHARA M , et al . JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome [J ] . Circ J , 2019 , 83 ( 5 ): 1085 ‑ 1196 .

CHHABRA S T , KAUR T , MASSON S , et al . Early onset ACS: An age based clinico‑epidemiologic and angiographic comparison [J ] . Atherosclerosis , 2018 , 279 : 45 ‑ 51 .

KRINGELAND E , TELL G S , MIDTBØ H , et al . Stage 1 hypertension, sex, and acute coronary syndromes during midlife: the Hordaland Health Study [J ] . Eur J Prev Cardiol , 2022 , 29 ( 1 ): 147 ‑ 154 .

MANFRINI O , CENKO E , BUGIARDINI R . Gender differences in residual risk factors for major adverse cardiovascular events following ACS and how to bridge the gap [J ] . Curr Atheroscler Rep , 2020 , 22 ( 11 ): 65 .

YAMAMOTO K , NATSUAKI M , MORIMOTO T , et al . Coronary artery disease without standard cardiovascular risk factors [J ] . Am J Cardiol , 2022 , 164 : 34 ‑ 43 .

CHEN J , ZHANG Y , LIU J , et al . Role of lipoprotein(a) in predicting the severity of new on‑set coronary artery disease in type 2 diabetics: A Gensini score evaluation [J ] . Diab Vasc Dis Res , 2015 , 12 ( 4 ): 258 ‑ 264 .

RAMPIDIS G P , BENETOS G , BENZ D C , et al . A guide for gensini score calculation [J ] . Atherosclerosis , 2019 , 287 : 181 ‑ 183 .

TANAKA T , MIKI K , AKAHORI H , et al . Comparison of coronary atherosclerotic disease burden between ST‑elevation myocardial infarction and non‑ST‑elevation myocardial infarction: Non‑culprit Gensini score and non‑culprit SYNTAX score [J ] . Clin Cardiol , 2021 , 44 ( 2 ): 238 ‑ 243 .

DOGANER Y C , AYDOGAN U , AYDOGDU A , et al . Relationship of cystatin C with coronary artery disease and its severity [J ] . Coron Artery Dis , 2013 , 24 ( 2 ): 119 ‑ 126 .

VAN DER LAAN S W , FALL T , SOUMARÉ A , et al . Cystatin C and cardiovascular disease: A mendelian randomization study [J ] . J Am Coll Cardiol , 2016 , 68 ( 9 ): 934 ‑ 945 .

WALLENTIN L , ERIKSSON N , OLSZOWKA M , et al . Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study [J ] . PLoS Med , 2021 , 18 ( 1 ): e1003513 .

WANG G N , SUN K , HU D L , et al . Serum cystatin C levels are associated with coronary artery disease and its severity [J ] . Clin Biochem , 2014 , 47 ( 16/17 ): 176 ‑ 181 .

ALMEIDA R , MARIANO L , GAVINA C , et al . The value of NT‑proBNP in early risk stratification of acute coronary syndromes [J ] . Rev Port Cardiol , 2006 , 25 ( 1 ): 71 ‑ 75 .

FAN J , MA J , XIA N , et al . Clinical value of combined detection of CK‑MB, MYO, cTnI and plasma NT‑proBNP in diagnosis of acute myocardial infarction [J ] . Clin Lab , 2017 , 63 ( 3 ): 427 ‑ 433 .

HAMAYA R , YONETSU T , KANAJI Y , et al . Interrelationship in the prognostic efficacy of regional coronary flow reserve, fractional flow reserve, high‑sensitivity cardiac troponin‑I and NT‑proBNP in patients with stable coronary artery disease [J ] . Heart Vessels , 2019 , 34 ( 3 ): 410 ‑ 418 .

NOPP S , VAN DER BENT M L , KRAEMMER D , et al . Circulatory miR‑411‑5p as a novel prognostic biomarker for major adverse cardiovascular events in patients with atrial fibrillation [J ] . Int J Mol Sci , 2023 , 24 ( 4 ): 3861 .

TANG Q J , LEI H P , WU H , et al . Plasma miR‑142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy [J ] . Acta Pharmacol Sin , 2019 , 40 ( 2 ): 208 ‑ 215 .

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

miR‑146、ApoE与急性冠脉综合征的相关性研究

基于TCGA数据构建乳腺癌上皮间质转化相关lncRNA的预后模型

构建基于自噬相关lncRNAs皮肤黑色素瘤预后模型

三七总皂苷通过长链非编码RNA对氧诱导视网膜病变小鼠新生血管的抑制作用

静脉血栓栓塞症预防健康教育的研究进展